Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy

Recently, Schlafen family member 11 (SLFN11) has been reported to increase the sensitivity of cancer cells to DNA-damaging agents, including platinum derivatives; thus, SLFN11 may be a predictive biomarker for platinum-based chemoradiotherapy (CRT). In this study, we examined whether SLFN11 expressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Seijiro, Kano, Satoshi, Murai, Junko, Suzuki, Takayoshi, Tsushima, Nayuta, Mizumachi, Takatsugu, Suzuki, Masanobu, Takashima, Tsuyoshi, Taniyama, Daiki, Sakamoto, Naoya, Fujioka, Yoichiro, Ohba, Yusuke, Homma, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892834/
https://www.ncbi.nlm.nih.gov/pubmed/36741698
http://dx.doi.org/10.3389/fonc.2022.978875

Ejemplares similares

Ejemplares similares